About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

NCT02175017·10 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Ono Pharmaceutical Co., Ltd.

Age

20–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Male or female ≥ 20 years of age
2. Histologically or cytologically confirmed non-small cell lung cancer
3. Diagnosis of NSCLC in stage IIIB/IV unsuited to radical radiotherapy according to UICC-TNM classification (7th edition) or recurrent NSCLC
4. Has at least one measurable lesion, as defined by the RECIST guideline (version 1.1)

You may not be if

1. Current or prior severe hypersensitivity to another antibody product
2. Multiple primary cancers

The record

StatusCompleted

PhasePhase 2

Taking part104

StartedJun 2014

UpdatedDec 9, 2024

Conditions

Advanced Non-small Cell Lung Cancer (NSCLC)

Where10

Goyang-si Clinical Site 103
Goyang-si, Gyeonggi-do, South Korea
Seongnam-si Clinical Site 104
Seongnam-si, Gyeonggi-do, South Korea
Cheongju-si Clinical Site 106
Cheongju-si, North Chungcheong, South Korea

Clareo Health | ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer